Clinical trials with N-isopropyl-alpha-(2-methylhydrazino)-p-toluamide hydrochloride in malignant lymphoma and other disseminated neoplasia.
D000230:Adenocarcinoma / Q000188:drug therapy; D000328:Adult; D000368:Aged; D000588:Amines / Q000627:therapeutic use*; D002283:Carcinoma, Bronchogenic / Q000188:drug therapy; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy; D002986:Clinical Trials as Topic; D006689:Hodgkin Disease / Q000188:drug therapy; D006801:Humans; D006834:Hydrazines / Q000627:therapeutic use*; D008223:Lymphoma / Q000188:drug therapy; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy; D009182:Mycosis Fungoides / Q000188:drug therapy; D009369:Neoplasms / Q000188:drug therapy*; D013736:Testicular Neoplasms / Q000188:drug therapy; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy; D009396:Wilms Tumor / Q000188:drug therapy
D000588:Amines; D006834:Hydrazines